Cantor Fitzgerald has expressed an optimistic outlook for financial markets in the near term, and into 2026. The firm ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...
Salesforce, Inc. (NYSE:CRM) is one of the Hot AI Stocks on Wall Street’s Radar. On December 5, Cantor Fitzgerald reiterated an “Overweight” rating on the stock with a $325.00 price target. The rating ...
Fintel on MSN
Cantor Fitzgerald upgrades SoundHound AI (SOUN)
Fintel reports that on December 12, 2025, Cantor Fitzgerald upgraded their outlook for SoundHound AI (NasdaqGM:SOUN) from ...
8d
Cantor has cut its Strategy price target by 60%, but wants you to know everything is going to be OK
Cantor Fitzgerald, a bank with some political ties, is the ninth-biggest shareholder in Strategy, a bitcoin treasury company ...
Lower adjusted net asset value multiple means Strategy can no longer issue equity at a premium, threatening its long-term ...
Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.
Cantor Fitzgerald analysts revised Strategy's stock price target to $229, down 59% from $560, citing a decrease in the value ...
Cantor Fitzgerald disclosed holding 58,000 shares of the Volatility Shares Solana ETF during the third quarter of this year.
Cryptopolitan on MSN
Cantor Fitzgerald reveals Solana ETF investment stake
Cantor Fitzgerald revealed a $1.28 million Solana ETF stake, boosting institutional investor interest immediately.
Cantor Fitzgerald slashed its MSTR price target by 60% but told clients that forced liquidations from Strategy remain an unwarranted concern.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback